Gamma-irradiated cornea allograft is effective for glaucoma surgery

Article

Gamma-irradiated cornea allograft is safe and effect for use in glaucoma surgery, according to a paper published in the latest issue of the Journal of Glaucoma.

Gamma-irradiated cornea allograft is safe and effect for use in glaucoma surgery, according to a paper published in the latest issue of the Journal of Glaucoma.

A team managed by Dr Scott Lawrence, Department of Ophthalmology, University of North Carolina, North Carolina, USA, reviewed 10 eyes of 10 consecutive patients who underwent primary or secondary glaucoma surgery using sterile cornea allograft.

The allograft covered the primary glaucoma tube shunt in three patients, coverage and revised glaucoma tube shunt in five patients, tectonic support of a revised trabeculectomy flap in one patients and the coverage of subconjunctival prolene sutures after surgical iridoplasty in one patient.

During the follow-up period ten cases presented with stable and biocompatible allografts. This was due to maintained clarity of the corneal tissue, absence of clinical signs of immunologic rejection or ocular inflammation and integrity of the sterile cornea/conjunctiva over the graft.

There were no complications during the follow-up and the cosmetic findings were satisfactory. The benefits of sterile cornea allograft for the coverage of glaucoma tube shints include tissue transparency, resilience and ease of surgical use.

For the abstract please click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.